Treatment of chronic hepatitis B with interferon-alpha: Cost-effectiveness in developing countries

National Medical Journal of India

Volumn 15, Issue 6, 2002, Pages 320-327

  Aggarwal, Rakesh ^a   Ghoshal, U C ^a   Naik, S R ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEVELOPING COUNTRY; DISEASE COURSE; DRUG COST; DRUG EFFICACY; FOLLOW UP; HEPATITIS B; HUMAN; INCOME; INDIA; LIFESPAN; LIVER CIRRHOSIS; MORTALITY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INDIA; INTERFERON-ALPHA; MALE; MARKOV CHAINS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0036872335     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
2. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301.
3. Perez V, Tanno H, Villamil F, Fay O. Recombinant interferon alfa-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J Hepatol 1990;11 (Suppl 1): S113-S117.
4. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis. Ann Intern Med 1993;119:312-23.
5. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 199l;114:629-34.
6. Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J, et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887-92.
7. Petrillo RP, Brunt EM, Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. Ann Intern Med 1991;115:113-15.
8. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122: 664-75.
9. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal. Hepatology 1995;22:1863-73.
10. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001;120:1828-53.
11. Thyagarajan SP, Jayaram S, Mohanavalli B. Prevalence of HBV in general population in India. In: Sarin SK, Singal AK (eds). Hepatitis B in India: Problems and prevention. New Delhi:CBS Publishers, 1996:5-16.
12. Guptan RC, Thakur V, Malhotra V, Sarin SK. Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian Indians. J Gastroenterol Hepatol 1998;13:675-9.
13. Mazumder DG, Chaudhuri S, Konar A, Santra A, Pal B, Sarkar S. Response to low-dose interferon in chronic liver disease due to hepatitis B virus infection. Indian J Gastroenterol 1998;17:97-9.
14. Sarin SK, Guptan RC, Thakur V, Malhotra S, Malhotra V, Banerjee K, et al. Efficacy of low-dose alpha interferon therapy in HBV-related chronic liver disease in Asian Indians: A randomized controlled trial. J Hepatol 1996;24:391-6.
15. Indian Association for Study of the Liver. Hepatitis B in India: Therapeutic options and prevention strategies-Consensus statements. Indian J Gastroenterol 2000;19 (Suppl 3):C54-C66.
16. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322-38.
17. Louis-Jacques O, Olson AD. Cost-benefit analysis of interferon therapy in children with chronic active hepatitis B. J Pediatr Gastroenterol Nutr 1997;24:25-32.
18. Fattovich G, Giustina G, Schalm. SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B: The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21:77-82.
19. DeJongh FE, Janssen HLA, de Man RA, Hop WCJ, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
20. D'Amico G, Marabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31:468-75.
21. Liaw Y-F, Lin D-Y, Chen T-J, Chu C-M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Liver 1989;9:235-41.
22. International Institute for Population Sciences (IIPS), ORC Macro. National Family Health Survey (NFHS-2), 1998-99, India. Mumbai:International Institute for Population Studies, 2000:178-9.
23. World Bank. The World Bank Group. Development data: Country data. Cited 20 December 2001. http://www.worldbank.org/data/countrydata/countrydata.html
24. Maynard JE, Kare MA, Alter MJ, Hadler SC. Control of hepatitis B by immunization: Global perspective. In: Zukerman AJ (ed). Viral hepatitis and liver disease. New York:Alan R. Liss, 1988:967-9.
25. Lok ASF, Wu P-C, Lai C-L, Lau JYN, Leung EKY, Wong LSK, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-7.
26. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5.
27. Yuen M-F, Hui C-K, Cheng C-C, Wu C-H, Lai Y-P, Lai C-L. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-45.
28. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY. et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001; 33:1527-32.
29. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
30. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003 (in press).